Completed PHASE3 INTERVENTIONAL 1-arm NCT01364181

The Impact of Udenafil on Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

The Impact of Udenafil on Exercise Capacity in Severe COPD Patients

Sponsor: Dong-A PharmTech Co., Ltd.

Conditions Chronic Obstructive Pulmonary Disease Dyspnea Pulmonary Hypertension

Interventions Udenafil

Updated 6 times since 2017 Last updated: Jun 17, 2011 Started: Mar 31, 2010 Primary completion: Mar 31, 2011 Completion: May 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Obstructive Pulmonary Disease and Dyspnea and is currently completed. Dong-A PharmTech Co., Ltd. leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong-A PharmTech Co., Ltd.
Seoul National University Hospital

Data source: Seoul National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seongnam-si, South Korea